Introduction {#Sec1}
============

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus (T2DM). In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia \[[@CR1]\]. This article summarizes properties of short- and long-acting GLP-1 analogs, providing useful information for choosing the most appropriate compound for individual patients.

Methods {#Sec2}
=======

The present paper is based on a review of recent publications on GLP-1 RA therapy and data from controlled clinical trials undertaken to investigate properties, functions, efficacy and safety of GLP RAs. Searches of PubMed were conducted for articles published between December 2013 and July 2014 using the terms "GLP-1 receptor agonist therapy", "GLP-1 and extraglycemic effects", "lixisenatide", "exenatide", "liraglutide", "dulaglutide", "albiglutide", and "long-acting GLP-1 RA".

For the introduction, we considered articles published between 1996 and 2013 on the biology and physiology of the incretin hormones and their role in the pathophysiology of T2DM. We focused on recent reviews on GLP-1 RA, meta-analyses and controlled clinical trials (January 2005 to October 2014). In particular, we analyzed controlled clinical trials comparing short- and long-acting GLP-1 RA, GLP-1 RA versus insulin, and GLP-1 versus oral agents. We also examined two meta-analyses: one around the efficacy and safety of incretin therapy, and the other comparing exenatide once-weekly or liraglutide once-daily with insulin glargine, exenatide twice-daily or placebo.

Our goal was to analyze the therapies for diabetes in use today and emphasize the mechanism and clinical efficacy of GLP-1 RA therapy. We analyze the molecules which are actually approved by Food Drug Administration (FDA) and European Medicines Agency (EMA).

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

The Physiological Role of Incretins {#Sec3}
===================================

The incretin notion is based on the observation that the insulin response from ingested glucose is larger and more sustained than that from intravenously administered glucose, suggesting that substances produced in the gastrointestinal tract in response to meals ("incretins") stimulate insulin release \[[@CR2], [@CR3]\]. Two incretins have been identified: gastric inhibitory polypeptide (GIP), which is secreted by enteroendocrine K-cells in the proximal gut, and glucagon-like peptide-1 (GLP-1), which is secreted mainly by L-cells located in the distal ileum. Within minutes of eating, the active forms of GIP and GLP-1 are released into the circulation and act by binding and activating specific G-protein coupled receptors expressed on β-cells and other targets, which rapidly increases exocytosis of insulin granules. Both GIP and GLP-1 are then rapidly inactivated by the ubiquitous serine protease dipeptidyl peptidase-4 (DPP-4). Long-term effects include stimulation of insulin synthesis \[[@CR4]\], an increase in β-cell proliferation and a reduction in apoptosis \[[@CR5]\]. GLP-1 also improves the glycemic profile by inhibiting glucagon secretion, delaying gastric emptying, and reducing food intake. GLP-1 may also improve glucose disposal in peripheral tissues (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6]--[@CR9]\]. GLP-1 may have an affect on tissues that are not directly involved in glucose metabolism, including protection against myocardial ischemia or reperfusion injury \[[@CR10], [@CR11]\]. In blood vessels, it protects against endothelial dysfunction \[[@CR12]\], and promotes endothelium-independent artery relaxation \[[@CR13]\]. It may have renal protective effects through increases in diuresis and natriuresis \[[@CR14], [@CR15]\]. These actions may lower blood pressure and have favorable effects on markers of cardiovascular risk, including brain natriuretic peptide and plasminogen activator inhibitor \[[@CR16]\].Fig. 1Physiology of GLP-1 secretion and action on GLP-1 receptors in different organs and tissues. GLP-1 is produced postprandially by intestinal L-cells. Through activation of insulin receptors on β-cells GLP-1 (like GIP) stimulates insulin biosynthesis and secretion and inhibits glucagon secretion in the pancreas, which in turn reduces hepatic gluconeogenesis. GLP-1 release also exerts protective effects on the heart and brain. Insulin sensitivity in the periphery is increased by improved insulin signaling and reduced gluconeogenesis. *GI* gastrointestinal, *GIP* gastric inhibitory polypeptide, *GLP*-*1* glucagon-like peptide-1. Modified with permission from Pratley and Gilbert \[[@CR106]\]

Pathophysiological Mechanism {#Sec4}
============================

In subjects with normal glucose tolerance, the incretin effect accounts for about two-thirds of the insulin response to an oral load, whereas in patients with T2DM this value is less than 20% \[[@CR3], [@CR17]\]. Thus, the incretin response may be particularly important during the postprandial period and impaired response may lead to postprandial hyperglycemia.

The hypothesis that meal-induced GLP-1 secretion is impaired in patients with T2DM versus control subjects is controversial. A large cross-sectional study by Toft-Nielsen et al. \[[@CR18]\] showed that meal-induced GLP-1 responses were significantly reduced in patients with T2DM; however, in other studies they were similar to those in healthy participants (Fig. [2](#Fig2){ref-type="fig"}), and were not significantly different in a meta-analysis of 189 patients with T2DM and 217 healthy controls \[[@CR19]\].Fig. 2Responses of \"total\" GLP to oral glucose or mixed meals in patients with T2DM and control subjects. Integrated responses of \"total\" GLP to oral glucose or mixed meals based on individual studies reporting integrated incremental \"total\" GLP-1 responses in patients with T2DM and an appropriate control group (weight-matched, non-diabetic participants) and using non-specific assays that measured intact and DPP-4-degraded forms of GLP-1. The response in patients with T2DM (mean ± SEM) is expressed as percentage of the mean value in the control group. \**P* \< 0.05 versus control. The *numbers in bars* indicate the number of patients with T2DM (*upper row*) and control participants (*lower row*) studied. *Light blue* oral glucose, *dark blue* mixed meal. *DPP*-*4* dipeptidyl peptidase-4, *GLP* glucagon-like peptide, *T2DM* type 2 diabetes mellitus, *SEM* standard error of mean. Modified with permission from Nauck et al. \[[@CR19]\]

A study performed under hyperinsulinemic--euglycemic clamp conditions, to maintain the same glucose and insulin levels in diabetic patients and matched control subjects, showed that GLP-1 response to oral glucose was reduced in patients with T2DM \[[@CR20]\]. Because high glucose levels are known to induce DPP-4 expression \[[@CR21]\], it has been hypothesized that chronic hyperglycemia may increase GLP-1 clearance, causing lower levels of circulating active GLP-1 \[[@CR22]\]. However, no reduction in elimination rates of GLP-1 has been observed in patients with T2DM and mild-to-moderate hyperglycemia \[[@CR23]\]. Thus, there appears to be some variation in GLP-1 secretion and/or inactivation, and in some cohorts the GLP-1 response was somewhat reduced, whereas in other studies such differences were not as apparent (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR19]\]. Impairment of the GLP-1 axis could be the consequence, rather than the cause, of hyperglycemia, establishing a vicious cycle that contributes to the maintenance of elevated glucose levels in T2DM, rather than to the pathogenesis of the disease.

Incretin-Based Therapies {#Sec5}
========================

Twenty-seven years after the first publication by Nauck in *Diabetologia* \[[@CR17]\], our understanding of the role of incretins in the pathophysiology of T2DM has made great advances \[[@CR22]\]. We now recognize that, although both GIP and GLP-1 stimulate insulin secretion in response to glycemic excursions, GLP-1 also influences gastric emptying, satiety and glucagon secretion \[[@CR24]\].

Native GLP-1 has not advanced as a therapeutic agent because of its rapid degradation by DPP-4 \[[@CR25]\]. The therapeutic potential of GLP-1 has been realized using two pharmacologic approaches; first, mimicking and focusing on GLP-1 via GLP-1 receptor agonists; and second, inhibiting the action of DPP-4 via DPP-4 inhibitors \[[@CR26], [@CR27]\].

A relevant difference between the DPP-4-resistant GLP-1 RAs and DPP-4 inhibitors is the route of administration: GLP-1 RAs require subcutaneous injection, whereas all DPP-4 inhibitors are oral agents, which may be preferred by patients. However, subcutaneous injection of GLP-1 RAs stimulates insulin secretion more strongly than oral ingestion of DPP-4 inhibitors \[[@CR28]\]. This difference is also due to the fact that, although DPP-4 inhibition results in supra-physiological levels of endogenous GLP-1, GLP-1 RAs provide pharmacological levels of stimulation and more glucose-lowering efficacy \[[@CR6], [@CR24], [@CR28]\]. Data from animal studies suggest that the effects of systemic versus local intestinal inhibition of DPP-4 activity may be different \[[@CR29]\]. DPP-4 inhibition may influence glycemia by activating incretin receptors, preventing the release of bioactive peptides and affecting parasympathetic control of the digestive tract \[[@CR29]\]. In addition, unlike DPP-4 inhibitors, GLP-1 RAs slow gastric emptying, increase satiety and promoting weight loss \[[@CR6], [@CR24], [@CR28]\]. The difference may be explained by the effect of DPP-4 inhibitors on the degradation of GIP and neuropeptide Y, which have opposing effects on gastric motility and satiety \[[@CR24]\].

The extraglycemic effects of incretin-based treatments are also promising. β-cell function is improved during treatment with incretin agents, and pre-clinical models show beneficial effects on β-cell regeneration and function. The positive effects of incretins on β-cells may explain, at least partly, the remission of diabetes documented in obese patients undergoing some types of bariatric surgery. Different bariatric surgery procedures result in distinct anatomical rearrangements of the gut axis with different responses in terms of gut hormone levels and remission of diabetes. The ability of GLP-1 to enhance postprandial insulin secretion in patients who have undergone Roux-en-Y bypass surgery may also result in the hyperinsulinemic hypoglycemia experienced by some patients \[[@CR30]\].

The potential cardiovascular benefits of incretins have attracted much attention. Reduction of blood pressure, improvement in lipid profile and endothelial/myocardial function have been documented in several pre-clinical and clinical studies, supporting potential beneficial effects on cardiovascular outcomes \[[@CR31]\]. Data from animal models suggest that the cardioprotective and vasodilatory effects of GLP-1 are independent of the cyclic adenosine monophosphate (cAMP)-linked GLP-1 receptor and are likely mediated by the GLP-1 (9--36) metabolite \[[@CR32]\].

Lønborg et al. showed that exenatide had a positive effect on myocardial salvage at the time of reperfusion in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention \[[@CR33]\]. The mechanism of exenatide-mediated protection against reperfusion injury is yet to be fully clarified. Two key phenomena in reperfusion injury appear to be the loss of mitochondrial integrity \[[@CR34]\] and myocyte hypercontracture associated with sarcolemmal rupture \[[@CR35]\]. A large body of experimental research suggests that reperfusion injury may be ameliorated by activation of a receptor-mediated survival pathway \[[@CR36]\]. This pathway is a target for GLP-1-mediated cardioprotection through activation of phosphoinositide-3-kinase \[[@CR10]\]. However, other possible targets for exenatide have been identified, including increased glucose uptake, inhibition of apoptotic factors, and activation of cAMP and cyclic guanosine monophosphate (cGMP). Thus, the cardioprotective action of GLP-1 receptor stimulation may occur through a number of pathways encompassing effects on metabolism, contractility and apoptosis. Other studies have shown that subcutaneous exenatide protects ischemia--reperfusion-induced endothelial dysfunction through the opening of adenosine triphosphate-sensitive potassium channels (K~ATP~ channels) \[[@CR37]\]. Ischemia--reperfusion impairs endothelium-dependent vasodilatation; however, pre-treatment with exenatide protects the endothelium from this injury \[[@CR37]\]. The endothelial protective effect of exenatide is almost completely prevented when a K~ATP~ channel blocker is administered before exenatide, suggesting that this effect of GLP-1 RA is mediated by K~ATP~ channel opening. Overall, the available results suggest that GLP-1 and its receptor agonists exert ischemic preconditioning through a nitric oxide (NO)-dependent pathway, of which K~ATP~ channels are key effectors. These findings represent the first set of evidence in human subjects for the effects of exenatide on pharmacological endothelial preconditioning, and provide a mechanistic explanation for this phenomenon. Additional studies are needed to investigate the mechanisms and their potential clinical implications in greater detail \[[@CR37]\].

GLP-1 receptors are widely expressed in the central nervous system (CNS) where they are generally associated with the regulation of appetite and satiety; however, data from pre-clinical models of Alzheimer's disease suggest that GLP-1 may have neurotrophic and neuroprotective actions, and reduce amyloid-beta accumulation, thus encouraging the successful translation of these data into new treatments for patients with neurodegenerative CNS disorders \[[@CR38]\].

Short-Acting GLP-1 RAs {#Sec6}
======================

Exenatide {#Sec7}
---------

Exenatide was the first incretin agent to be approved for glycemic control in diabetes. The sequence of this 39-amino acid synthetic peptide is based on exendin-4 from the lizard *Heloderma suspectum* (Gila monster), sharing 53% homology with human GLP-1 \[[@CR39]\]. It binds to the pancreatic GLP-1 receptor and has many of the glucoregulatory properties of human GLP-1 \[[@CR40]\], with a substantially longer plasma half-life than GLP-1 due to the presence of an N-terminal serine in exendin-4 instead of alanine \[[@CR41]\]. The 5--10 μg dose is administered by subcutaneous injection twice-daily within 1 h of eating a main meal.

Exenatide shares some of the glucoregulatory effects of GLP-1, but is resistant to DPP-4 degradation. It has a number of actions, including enhancing glucose-dependent insulin secretion \[[@CR42]\], suppressing postprandial glucagon secretion, slowing gastric emptying \[[@CR43]\], and reducing caloric intake \[[@CR44]\]. Pre-clinical studies have shown that exenatide also increases pancreatic β-cell mass and clinical studies have shown that it improves β-cell function \[[@CR45], [@CR46]\]. The efficacy and safety of exenatide administered in patients with T2DM not adequately controlled with oral agents (i.e., metformin, sulfonylurea, or sulfonylurea plus metformin) has been demonstrated in a series of 30-week clinical studies \[[@CR47]--[@CR49]\]. In these studies, up to 46% of exenatide-treated patients achieved target goals for hemoglobin A~1c~ (HbA~1c~) ≤7% as prescribed by the American Diabetes Association (ADA) guidelines, compared with up to 13% of placebo-treated patients \[[@CR50]\]. Mean change from baseline in body weight in these trials was greater in exenatide-treated patients (−1.6 to −2.8 kg) compared to placebo-treated subjects (−0.3 to −0.9 kg) \[[@CR47]--[@CR49]\].

The efficacy of exenatide as adjunctive treatment in patients with T2DM receiving thiazolidinedione was evaluated in a randomized, double-blind, placebo-controlled trial \[[@CR51]\]. After 16 weeks of treatment, patients treated with exenatide showed significant improvements in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and homeostasis model assessment of β-cell function (HOMA-B), and promoted weight loss compared with placebo \[[@CR51]--[@CR55]\]. Exenatide also improved daily mean postprandial glucose concentrations (PPG) (based on self-monitored blood glucose). The incidence of mild-to-moderate hypoglycemia was similar in both groups with no severe hypoglycemia reported \[[@CR51]\].

Long-term data describing the effects of exenatide in the treatment of patients with T2DM have also been reported \[[@CR52], [@CR56]\]. Patients enrolled in phase III clinical trials have completed open-label extensions of up to 3.5 years. In addition to exenatide, patients were also receiving metformin, sulfonylurea, or a combination of the two therapies, as well as other agents that reduce cardiovascular (CV) risk. At baseline, 41% were receiving angiotensin-converting enzyme inhibitors, 38% were receiving 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors ("statins"), and 39% were receiving aspirin. At the end of either 3 years or 3.5 years of treatment and follow-up, patients showed significant reductions in HbA~1c~, FPG, and body weight from baseline \[[@CR52]\]. In the 3-year completer group, 46% of patients achieved HbA~1c~ of ≤7% and 30% achieved HbA~1c~ of ≤6.5%. At the 82-week interim analysis, 81% of patients had lost weight \[[@CR56]\]. In general, after 3 years of exenatide, overweight/obese patients with greater body mass index (BMI) at baseline lost more weight, with 84% of patients losing weight and 50% of patients losing at least 5% of their body weight. Improvements in HbA~1c~, FPG, and body weight with exenatide were observed regardless of age and were sustained through 3.5 years of treatment \[[@CR52]\]. Over the 3 to 3.5 years of follow-up, patients treated with exenatide, which was generally well tolerated, experienced favorable effects on hepatic injury biomarkers and CV risk factors. Exenatide-treated patients with elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at baseline significantly improved at 3 years (*P* \< 0.001), while patients with normal ALT and AST values at baseline had little or no change. In the 3.5-year completer group, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and systolic and diastolic blood pressure all showed significant improvements relative to baseline. The most frequently reported adverse events (AEs) over the course of the study were mild-to-moderate nausea (59%) and hypoglycemia (40%) \[[@CR52]\].Generally, the incidence of nausea was highest during the first few weeks of treatment, and a significant reduction was reported after this initial period \[[@CR52], [@CR56]\]. A single event of severe hypoglycemia occurred in 1 patient who was taking concomitant metformin and sulfonylurea \[[@CR52]\]. A review of current clinical data shows the estimated incidence of acute pancreatitis related to any drug therapy is approximately 0.1% to 2% \[[@CR57]\]. Acute pancreatitis has been reported in patients treated with GLP-1 receptor agonist therapy, although no causal relation has been found. A retrospective, cohort study found that patients with T2DM (*N* = 337,067) may have nearly a threefold greater risk of acute pancreatitis compared with patients without diabetes (*N* = 337,067) \[[@CR58]\]. During the clinical development of exenatide, the incidence of acute pancreatitis in exenatide-treated patients was lower than that observed in patients receiving insulin or placebo \[[@CR59]\]. A recent claims-based active drug safety surveillance system revealed that the risk of acute pancreatitis in patients treated with exenatide or sitagliptin (relative risk: 1.0 for either agent) was comparable to that of patients treated with metformin or glyburide \[[@CR60]\]. In addition, post hoc analyses of serious adverse events reported in clinical trials have not found an increased risk of pancreatitis with GLP-1 receptor agonists \[[@CR61]\]. Although postmarketing surveillance data with exenatide are not sufficient to definitively establish drug-related causality \[[@CR59], [@CR60]\], exenatide therapy should be stopped in patients who exhibit symptoms of acute pancreatitis.

Exenatide was compared with the insulin analogs biphasic insulin aspart 70/30 (BIAsp 30) \[[@CR62]\] and insulin glargine \[[@CR63]\]. Results from these trials suggest that exenatide was not inferior to insulin therapy in terms of HbA~1c~ reduction, and may provide better postprandial glycemic control together with body weight decrease \[[@CR64]\]. It has been suggested that the insulin dosages administered in these studies may not have been optimal \[[@CR65]\]. The mean daily dose in the study comparing exenatide to BIAsp 30 \[[@CR62]\] was 24.4 units, which reduced the mean HbA~1c~ level by 1.0%. Meanwhile in the INITIATE study \[[@CR66]\], the daily dose was threefold higher (78.5 units) and this provided a 2.8% reduction in HbA~1c~. The daily dose in the study comparing exenatide to insulin glargine \[[@CR63]\] was 25 units compared to 47 units in the treat-to-target trial \[[@CR67]\]. Thus, it remains to be determined how exenatide compares with optimal insulin dosing \[[@CR68]\].

From studies mentioned above, exenatide treatment was not inferior to insulin in HbA~1c~ reduction and provided better control of PPG, making it a potential alternative treatment for T2DM.

Lixisenatide {#Sec8}
------------

Lixisenatide is a selective GLP-1 receptor agonist with once-daily administration that was approved in Europe in 2013 for the treatment of T2DM \[[@CR69]--[@CR72]\]. Data from phase II/III studies reveal that lixisenatide 20 µg significantly lowers HbA~1c~ and reduces postprandial hyperglycemia. Two-hour postprandial glucose excursions were reduced by approximately 5 mmol/l compared to placebo after a standard meal \[[@CR73]\].

Once-daily lixisenatide was significantly better at controlling PPG after a standard solid breakfast compared with liraglutide in a 28-day clinical trial \[[@CR74]\], confirming previous findings \[[@CR69], [@CR72], [@CR75]\]. Compared with liraglutide, lixisenatide was also significantly better at reducing postprandial levels of insulin, C-peptide and glucagon. Whereas both lixisenatide and liraglutide lowered HbA~1c~ and body weight over the course of the 28-day study, differences in their efficacy over the course of the day were apparent, and there was also a possible difference in their pharmacokinetic profiles \[[@CR69], [@CR76]\]. Lixisenatide was better at controlling morning glycemia, while liraglutide provided better fasting and postprandial control.

Long-Acting GLP-1 RA {#Sec9}
====================

Liraglutide {#Sec10}
-----------

Liraglutide is a human GLP-1 analog in which lysine 34 is substituted with arginine, and lysine 26 has a C16 acyl chain attached \[[@CR77]\]. These modifications improve the absorption and extend the half-life compared to native GLP-1, allowing once-daily administration. After subcutaneous administration, maximum concentrations are achieved in 9--14 h, and half-life is 13 h \[[@CR78], [@CR79]\]. Reductions in HbA~1c~ ranged from 0.6% to 1.6% in clinical trials of liraglutide administered once-daily at 0.6 to 1.8 mg, alone or in combination with other agents \[[@CR80]--[@CR84]\].

The 26-week LEAD-6 trial (effect of liraglutide or exenatide added to an ongoing treatment on blood glucose control in subjects with type 2 diabetes) compared once daily liraglutide 1.8 mg to twice daily exenatide 10 µg in patients with T2DM inadequately controlled with metformin, a sulfonylurea, or both. In this trial liraglutide was associated with significantly greater reductions in mean HbA~1c~ (−1.1% vs. −0.8%) and fasting plasma glucose (−29 vs. −11 mg/dL) (*P* \< 0.0001 for both) \[[@CR85]\]. In a 14-week extension of this trial, patients who had switched to liraglutide had additional reductions in mean fasting glucose, as well as HbA~1c~ (from 7.2% at week 26 to 6.9% at week 40), whereas patients who continued to receive liraglutide maintained the HbA~1c~ reductions achieved in the 26-week trial \[[@CR85]\]. In other trials, reductions in FPG with liraglutide ranged from 13 to 43 mg/dL \[[@CR80]--[@CR84]\]. In the LEAD-6 trial, liraglutide had a greater effect on fasting glucose, while exenatide was more effective on PPG \[[@CR85]\]. As with exenatide, liraglutide is associated with dose-dependent weight loss, ranging from 1.0 to 3.2 kg in clinical trials \[[@CR80], [@CR82]--[@CR85]\], including those examining treatment regimens combining liraglutide with a sulfonylurea, which when given as monotherapy is associated with weight gain \[[@CR83]\]. Patients whose BMI exceeded 35 kg/m^2^ derived the greatest absolute benefit (weight loss up to −4.4 kg). Reductions in systolic blood pressure with liraglutide 0.6--1.8 mg ranged from 0.6 to 6.7 mmHg \[[@CR80]--[@CR84]\]. In the LEAD-6 extension trial, switched patients experienced further reductions in systolic blood pressure (−2.2 ± 0.88 mmHg; *P* = 0.0128) \[[@CR86]\]. Compared with placebo or active comparators, liraglutide significantly improved markers of β-cell function, including HOMA-B, proinsulin--insulin ratio, and proinsulin--C-peptide ratio \[[@CR81]--[@CR84]\]. Compared with placebo, liraglutide significantly increases first-phase insulin secretion and maximum β-cell insulin secretory capacity \[[@CR87]\].

Exenatide {#Sec11}
---------

Exenatide has been developed also as a once-weekly formulation \[exenatide long-acting release (exenatide LAR)\] that is approved for treating T2DM \[[@CR88]--[@CR91]\]. In the exenatide LAR formulation, the active peptide is incorporated in poly-([d]{.smallcaps},[l]{.smallcaps}-lactic-co-glycolic acid) matrix that provides controlled delivery \[[@CR92]\], allowing steady-state concentrations to be achieved in 6--10 weeks and providing a median half-life of 2 weeks \[[@CR64], [@CR90]\]. FPG levels are improved after 2 weeks of treatment \[[@CR89]\]. Studies have shown that exenatide once-weekly and liraglutide provide better glycemic control than exenatide twice-daily \[[@CR85], [@CR90], [@CR91]\]. Two randomized open-label studies found significantly better glycemic control with the once-weekly formulation compared to the twice-daily formulation \[[@CR90], [@CR91]\]. The once-weekly formulation reduced HbA~1c~ by 1.6% after 24 weeks \[[@CR91]\] and 1.9% after 30 weeks \[[@CR90]\], compared to 0.9% after 24 weeks and 1.5% after 30 weeks with the twice-daily formulation. Weight loss was similar in all groups compared \[[@CR90], [@CR91]\].

In the DURATION-6 study, a 26-week, open-label, randomized, parallel-group study conducted at 105 sites in 19 countries, Buse et al. compared the efficacy and safety of liraglutide once-daily (1.8 mg) with exenatide once-weekly (2 mg) in 912 patients with T2DM \[[@CR93]\]. They found that exenatide LAR and liraglutide both improved glycemic control and were associated with weight loss. Reductions in HbA1c and weight loss were greater in the liraglutide group than in the exenatide LAR group, while adverse gastrointestinal events and withdrawals due to adverse events were more frequent in the liraglutide group. The incidence of mild hypoglycemia was similar in both groups, and no major hypoglycemic events were reported. Patient-reported outcomes improved in both groups.

Exenatide and liraglutide have provided better glycemic control than other anti-hyperglycemic drugs in comparative studies. Exenatide LAR was more effective than maximum-labeled doses of exenatide twice-daily \[[@CR90], [@CR91]\], sitagliptin and pioglitazone \[[@CR88]\], and insulin glargine \[[@CR89]\] in patients treated with oral anti-hyperglycemic drugs. Exenatide once-weekly reduced HbA~1c~ to a greater extent than sitagliptin in drug-naive patients; it was not inferior to metformin, but did not achieve non-inferiority to pioglitazone \[[@CR93]\]. The maximum-labeled dose of liraglutide (1.8 mg) provided better glycemic control than exenatide twice-daily \[[@CR85]\], sitagliptin \[[@CR95]\], insulin glargine \[[@CR83]\], and submaximal doses of glimepiride \[[@CR80]\] and rosiglitazone \[[@CR81]\]. The reductions in HbA1c noted for these long-acting GLP-1 receptor agonists in comparator-controlled trials were generally greater than those of oral anti-hyperglycemic drugs and basal insulin \[[@CR81]--[@CR83], [@CR88]--[@CR91], [@CR93]--[@CR95]\].

It is important to note that, in the studies mentioned above, liraglutide was administered at the maximum dose of 1.8 mg and no studies have compared exenatide LAR with liraglutide twice-daily 1.2 mg or determined the relative efficacies of the available injectable therapies for glycemic control.

Scott et al. \[[@CR96]\] performed a network meta-analysis estimating the relative difference in HbA1c for exenatide, exenatide LAR, insulin glargine and liraglutide 1.2 and 1.8 mg compared to placebo based on a combination of direct and indirect clinical evidence. The analysis suggests that exenatide LAR and both doses of liraglutide are associated with clinically important improvements in HbA1c, as shown previously in clinical trials.

While the direct comparison identified a significantly greater HbA1c reduction for liraglutide 1.8 mg compared to exenatide LAR, this network meta-analysis, which also includes indirect data from additional trials, did not identify important differences in HbA1c reduction between the treatments \[[@CR96]\].

Albiglutide {#Sec12}
-----------

One of the newer long-acting GLP-1 RA is albiglutide, which was approved by the FDA in April 2014. It is a dimer of two copies of 30-amino acid fused to human albumin, and a single amino acid substitution (glycine to alanine), and achieves resistance to DPP-4 degradation \[[@CR97]\]. The efficacy and safety of albiglutide is demonstrated in the HARMONY clinical trials. Data from these trials have shown that albiglutide, in monotherapy or as add-on to other diabetes therapies, lowered HbA1c levels when compared with sitagliptin, glimepiride, pioglitazone and insulin lispro \[[@CR98]\].

Comparison data between albiglutide and lispro insulin in HARMONY-6 trial, in which it met non-inferiority criteria, suggest that this long-acting GLP-1 RA is a valid alternative to lispro insulin in add-on basal insulin. Another finding was the weight loss ability of albiglutide compared to weight gain in patients treated with lispro insulin \[[@CR99]\].

In the HARMONY-7 clinical trial, it was demonstrated that liraglutide at a dose of 0.6 mg titrated to 1.8 mg was more effective than albiglutide (at a dose of 30 mg titrated to 50 mg), but gastrointestinal adverse event was more frequent in liraglutide treatment \[[@CR100]\].

Dulaglutide {#Sec13}
-----------

Another once-weekly GLP-1 RA molecule approved for the treatment of T2DM is dulaglutide. It consists of a link between two GLP-1 analog chains and immunoglobulin G fragment. This structure confers a slower absorption and reduced rate of renal clearance \[[@CR101]\]. The AWARD (Assessment of weekly Administration of Dulaglutide) clinical trials assessed the efficacy and safety of dulaglutide as monotherapy and as add-on diabetes therapy. This newer molecule is compared to other hypoglycemic medications such as short-acting exenatide, liraglutide, sitagliptin, metformin and insulin lispro. The results have shown a reduction of HbA1c raging from −0.78 to −1.51% \[[@CR102]\]. In particular in the AWARD-6 trial, the efficacy of dulaglutide was comparable to its primary competitor, liraglutide. The reduction of HbA1c was −1.42% with dulaglutide and −1.36% with liraglutide. A significant greater reduction of weight loss was obtained in liraglutide group, although both molecules produced significant weight loss from baseline \[[@CR103]\]. Other clinical trials are investigating the efficacy of dulaglutide in combination with insulin glargine and the safety in patients with moderate and severe chronic kidney disease.

Conclusion {#Sec14}
==========

Although most of the benefits of GLP-1 can be exerted by both long-acting and short-acting GLP-1 analogs, the short-acting preparation of exenatide offers the additional benefit of greater decelerating gastric emptying, which appears to be the key factor driving the reduction of postprandial glycemia \[[@CR104]\]. Such additional "flattening" of postprandial glycemia seems to complement the predominant reduction of fasting glycemia achieved with a long-acting insulin. In the study by Buse et al., the short duration of exenatide action is illustrated by the fact that glycemic excursions following lunch---the meal that did not directly follow an injection of exenatide---did not differ from those with placebo \[[@CR85]\].

It should be noted that exenatide twice-daily (BID) and liraglutide, which were compared in the LEAD-6 study, have different half-lives. Exenatide has a half-life of 2--4 h, which is similar to insulin aspart (3--5 h) or lispro (2--5 h); whereas the half-life of liraglutide (13 h) is comparable to that of detemir (14 h). As a consequence, exenatide BID appears to be more suitable for the treatment of patients with predominantly postprandial hyperglycemia, whereas liraglutide as well as the other long-acting GLP-1 RAs would be more suitable for patients with predominantly fasting hyperglycemia.

Interestingly, with regard to the effects on gastric motility, glucose profiles and studies with long-acting GLP-1 analogs have suggested that tachyphylaxis---a weakening response over time---may occur with increasing drug exposure and concentrations. Comparatively, with the fluctuating plasma levels of exenatide observed with twice-daily injections, deceleration of gastric emptying is fully maintained.

Thus, although most of the current developments in the field of incretin mimetics aim to increase half-lives and extend injection intervals, these agents in combination with basal insulin preparations may be a promising area for short-acting compounds. Perhaps for this reason, clinical trials of additional short-acting incretin mimetics, such as lixisenatide, are ongoing, with the aim of combining these drugs with basal insulin. On the other hand, the potential advantages of long-acting GLP-1 analogs include a more pronounced reduction of fasting glucose, less frequent injections and lower rates of nausea \[[@CR85]\].

Clearly, glycemic control is not the only goal of modern diabetes therapy. Insulin treatment often increases body weight, whereas incretin mimetics promote weight loss, which is recommended for most patients with this condition. Results from a pilot study \[[@CR105]\], suggest that the weight-lowering effect of exenatide may predominate over the insulin-induced weight gain. For this reason, adding a GLP-1 analog may help to increase quality of life during insulin therapy by compensating for its tendency to cause weight gain.

It should be emphasized that when added to either sulfonylureas or insulin, GLP-1 RAs are associated with increased risk of hypoglycemia. Therefore, accurate titration of insulin doses by glucose-self-monitoring is recommended when such combinations are prescribed.
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